Xing Du constructed anti-FcRL1 immunotoxin and evaluated the specific cytotoxicity for the treatment of FcRL1-positive malignancies, including CLL, HCL, FL, MCL, and other B-non-Hodgkin lymphomas (NHLs) in vitro. This evidence concerns the gene FCRL1 and mantle cell lymphoma.